Tesofensine
A medication that blocks reuptake of serotonin, dopamine, and norepinephrine — originally developed for Alzheimer's and Parkinson's but showed significant weight loss in clinical trials. Reduces appetite through brain signaling in appetite centers. A different approach than GLP-1 medications and other peptide-based weight loss treatments.
Dosage
0.25-1.0 mg oral once daily in the morning
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Oral (capsule)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Weight Loss
12.8 kg average loss in 6 months at 0.5 mg — roughly double GLP-1 agonists.
Appetite Suppression
Triple monoamine reuptake inhibition addresses homeostatic and hedonic eating.
Energy Expenditure
Increases metabolic rate through stimulation of the nervous system.
Mechanism of Action
Tesofensine is a novel triple monoamine reuptake inhibitor (TRI) that simultaneously blocks the presynaptic reuptake transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT). Originally developed by NeuroSearch as NS2330 for neurodegenerative diseases, it was repurposed for obesity after clinical trials for Alzheimer's and Parkinson's disease unexpectedly revealed significant weight loss in treated patients.
The weight loss mechanism involves all three monoamine systems working in concert. Serotonin (5-HT) reuptake inhibition increases serotonergic tone in the hypothalamic appetite centers, particularly the paraventricular nucleus and ventromedial hypothalamus. Elevated synaptic serotonin activates 5-HT2C receptors on POMC neurons, promoting the release of alpha-MSH, which activates MC4R and produces satiety. This is the same pathway targeted by lorcaserin (Belviq), but tesofensine adds two additional mechanisms. Norepinephrine reuptake inhibition activates alpha-1 and beta-adrenergic receptors in the lateral hypothalamus, reducing appetite and increasing sympathetic nervous system activity, which raises basal metabolic rate and thermogenesis.
The dopamine reuptake inhibition component may be the most important differentiator. By increasing dopamine availability in the mesolimbic reward pathway (nucleus accumbens, ventral tegmental area), tesofensine may reduce the drive for food reward-seeking behavior — the compulsive eating of palatable, high-calorie foods that is mediated by dopamine signaling in the same circuits involved in addiction. This addresses a component of obesity that pure appetite suppressants miss: the hedonic (pleasure-driven) eating that overrides homeostatic satiety signals. Phase II clinical trials demonstrated remarkable efficacy — the 0.5 mg dose produced approximately 12.8 kg weight loss over 6 months, roughly double what GLP-1 receptor agonists typically achieve — though cardiovascular monitoring is necessary due to increases in heart rate associated with the noradrenergic and dopaminergic effects.
Regulatory Status
Not FDA approved. Phase III trials ongoing (Saniona). Approved in Mexico (2023) for obesity. Available through some international pharmacies and compounding sources.
Risks & Safety
Common
increased heart rate, dry mouth, insomnia, constipation, nausea, dizziness.
Serious
cardiovascular effects (sustained elevated heart rate), mood changes and potential psychiatric effects (all three brain chemical systems affected), suicidal ideation (class warning for CNS-active drugs).
Rare
serotonin syndrome if combined with other serotonergic drugs, significant heart rhythm problems. Cardiovascular monitoring recommended.
Compare Tesofensine With
Research Papers
No research papers indexed yet. Papers are fetched from PubMed weekly.
Frequently Asked Questions
What is Tesofensine?
A medication that blocks reuptake of serotonin, dopamine, and norepinephrine — originally developed for Alzheimer's and Parkinson's but showed significant weight loss in clinical trials. Reduces appetite through brain signaling in appetite centers. A different approach than GLP-1 medications and other peptide-based weight loss treatments.
What is Tesofensine used for?
A medication that blocks reuptake of serotonin, dopamine, and norepinephrine — originally developed for Alzheimer's and Parkinson's but showed significant weight loss in clinical trials. Reduces appetite through brain signaling in appetite centers. A different approach than GLP-1 medications and other peptide-based weight loss treatments.
What is the dosage for Tesofensine?
Clinical trials: 0.25-1.0 mg oral once daily in the morning. Phase II demonstrated dose-dependent weight loss. 0.5 mg dose showed optimal efficacy/safety balance. No established commercial dosing.
What are the side effects of Tesofensine?
Common: increased heart rate, dry mouth, insomnia, constipation, nausea, dizziness. Serious: cardiovascular effects (sustained elevated heart rate), mood changes and potential psychiatric effects (all three brain chemical systems affected), suicidal ideation (class warning for CNS-active drugs). Rare: serotonin syndrome if combined with other serotonergic drugs, significant heart rhythm problems. Cardiovascular monitoring recommended.
How does Tesofensine work?
Tesofensine is a novel triple monoamine reuptake inhibitor (TRI) that simultaneously blocks the presynaptic reuptake transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT). Originally developed by NeuroSearch as NS2330 for neurodegenerative diseases, it was repurposed for obesity after clinical trials for Alzheimer's and Parkinson's disease unexpectedly revealed significant weight loss in treated patients. The weight loss mechanism involves all three monoamine systems working in concert. Serotonin (5-HT) reuptake inhibition increases serotonergic tone in the hypothalamic appetite centers, particularly the paraventricular nucleus and ventromedial hypothalamus. Elevated synaptic serotonin activates 5-HT2C receptors on POMC neurons, promoting the release of alpha-MSH, which activates MC4R and produces satiety. This is the same pathway targeted by lorcaserin (Belviq), but tesofensine adds two additional mechanisms. Norepinephrine reuptake inhibition activates alpha-1 and beta-adrenergic receptors in the lateral hypothalamus, reducing appetite and increasing sympathetic nervous system activity, which raises basal metabolic rate and thermogenesis. The dopamine reuptake inhibition component may be the most important differentiator. By increasing dopamine availability in the mesolimbic reward pathway (nucleus accumbens, ventral tegmental area), tesofensine may reduce the drive for food reward-seeking behavior — the compulsive eating of palatable, high-calorie foods that is mediated by dopamine signaling in the same circuits involved in addiction. This addresses a component of obesity that pure appetite suppressants miss: the hedonic (pleasure-driven) eating that overrides homeostatic satiety signals. Phase II clinical trials demonstrated remarkable efficacy — the 0.5 mg dose produced approximately 12.8 kg weight loss over 6 months, roughly double what GLP-1 receptor agonists typically achieve — though cardiovascular monitoring is necessary due to increases in heart rate associated with the noradrenergic and dopaminergic effects.
How is Tesofensine administered?
Tesofensine is administered via oral (capsule).
What is the half-life of Tesofensine?
The half-life of Tesofensine is 192-216 hours (8-9 days).
Is Tesofensine legal?
Not FDA approved. Phase III trials ongoing (Saniona). Approved in Mexico (2023) for obesity. Available through some international pharmacies and compounding sources.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
Cagrilintide
A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.